News

selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis

May 30, 2023

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late…

selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

September 12, 2022

News

Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12,…

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

May 9, 2022

News

Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022…

selectION Secures $5M Promissory Note

September 16, 2020

News

si-544, a Kv1.3 blocker with class leading selectivity and excellent preclinical safety profile, scheduled to advance towards clinical development in early 2021 SAN DIEGO, September 16, 2020 – selectION, Inc.…

selectION, Inc. Announces $4.1M Series A Investment

May 31, 2019

News

SAN DIEGO, May 31, 2019 – selectION, Inc., a biotherapeutic company focused on the development of peptide ion channel blockers with class leading selectivity, announced today it has received a…

selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board

November 30, 2018

News

SAN DIEGO, November 30, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board

August 29, 2018

News

SAN DIEGO, August 29, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

selectION appoints Antonius Schuh as new CEO

May 3, 2018

News

Dr. Schuh has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences industries and has served as CEO of five life sciences companies, including Arcturus…

News

selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis

selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

selectION Secures $5M Promissory Note

selectION, Inc. Announces $4.1M Series A Investment

selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board

selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board

selectION appoints Antonius Schuh as new CEO

Site Search

News Categories

Recent News

About

Recent News

Contact